AXL vs TSLA

The company exhibits weak fundamental health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm financial distress risk. Despite a recent strong price run-up (+44.8% 1Y), profitability is thin, growth is negative, and leverage is extremely high (Debt/Equity: 3.81). Valuation metrics are mixed, with a low P/S of 0.17 suggesting potential undervaluation, but elevated P/E of 23.66 and negative earnings growth raise concerns. Analysts concur with a 'hold' rating, aligning with the uncertain outlook.

Tesla's deterministic health is stable with a Piotroski F-Score of 4/9, but its valuation is fundamentally disconnected from current performance. The Graham Number ($22.85) and Intrinsic Value ($7.42) indicate extreme overvaluation relative to the current price of $343.25. With negative YoY revenue growth (-3.10%) and a collapse in earnings growth (-60.60%), the P/E ratio of 323.82 is unsustainable. Technical trends and insider activity are both strongly bearish, suggesting a significant correction is likely.